Effect of Vitamin E and Alpha Lipoic Acid in Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled, Open-Label, Prospective Clinical Trial (VAIN Trial)


Objective: Antioxidants, including alpha lipoic acid (ALA) and vitamin E, are efficacious for the treatment of nonalcoholic fatty liver disease (NAFLD). The objective was to evaluate the effects of ALA and vitamin E alone or combined as therapy for patients with NAFLD and nonalcoholic steatohepatitis (NASH). Design: Placebo-controlled, open-label, prospective study in which patients with NAFLD and NASH were randomized to treatment with ALA 300 mg (n = 40), vitamin E 700 IU (n = 40), ALA 300 mg plus vitamin E 700 IU (n = 40), or placebo (n = 35) daily for 6 months. Body mass index, homeostasis model assessment scores, fibrosis and steatosis markers, and diagnostic laboratory tests were assessed at baseline and at the end of the study. Results: Treatment with ALA and vitamin E alone or in combination, improved inflammatory cytokine levels, steatosis scores, homeostasis model assessment scores, and triglyceride levels after 6 months relative to baseline. Conclusion: Alpha lipoic acid and vitamin E, either alone or in combination, were effective treatments for patients with NAFLD and NASH.

Share and Cite:

Basu, P. , Shah, N. , Aloysius, M. and Brown Jr., R. (2014) Effect of Vitamin E and Alpha Lipoic Acid in Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled, Open-Label, Prospective Clinical Trial (VAIN Trial). Open Journal of Gastroenterology, 4, 199-207. doi: 10.4236/ojgas.2014.45030.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Erickson, S.K. (2009) Nonalcoholic Fatty Liver Disease. The Journal of Lipid Research, 50, S412-S416.
[2] Lazo, M., Hernaez, R., Bonekamp, S., Kamel, I.R., Brancati, F.L., Guallar, E., et al. (2011) Non-Alcoholic Fatty Liver Disease and Mortality among US Adults: Prospective Cohort Study. BMJ, 343, d6891.
[3] Angulo, P. (2002) Nonalcoholic Fatty Liver Disease. The New England Journal of Medicine, 346, 1221-1231.
[4] Szczepaniak, L.S., Nurenberg, P., Leonard, D., Browning, J.D., Reingold, J.S., Grundy, S., et al. (2005) Magnetic Resonance Spectroscopy to Measure Hepatic Triglyceride Content: Prevalence of Hepatic Steatosis in the General Population. American Journal of Physiology—Endocrinology and Metabolism, 288, E462-E468.
[5] Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., et al. (2002) Expanding the Natural History of Nonalcoholic Steatohepatitis: From Cryptogenic Cirrhosis to Hepatocellular Carcinoma. Gastroenterology, 123, 134-140.
[6] Hijona, E., Hijona, L., Arenas, J.I. and Bujanda, L. (2010) Inflammatory Mediators of Hepatic Steatosis. Mediators of Inflammation, 2002, Article ID 837419.
[7] Ibrahim, S.H., Kohli, R. and Gores, G.J. (2011) Mechanisms of Lipotoxicity in NAFLD and Clinical Implications. Journal of Pediatric Gastroenterology and Nutrition, 53, 131-140.
[8] Nehra, V., Angulo, P., Buchman, A.L. and Lindor, K.D. (2001) Nutritional and Metabolic Considerations in the Etiology of Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences, 46, 2347-2352.
[9] Schattenberg, J.M. and Schuppan, D. (2011) Nonalcoholic Steatohepatitis: The Therapeutic Challenge of a Global Epidemic. Current Opinion in Lipidology, 22, 479-488.
[10] Neuschwander-Tetri, B.A. (2010) Hepatic Lipotoxicity and the Pathogenesis of Nonalcoholic Steatohepatitis: The Central Role of Nontriglyceride Fatty Acid Metabolites. Hepatology, 52, 774-788.
[11] Gentile, C.L. and Pagliassotti, M.J. (2008) The Role of Fatty Acids in the Development and Progression of Nonalcoholic Fatty Liver Disease. The Journal of Nutritional Biochemistry, 19, 567-576.
[12] Solis-Herruzo, J.A., Garcia-Ruiz, I., Perez-Carreras, M. and Munoz-Yague, M.T. (2006) Non-Alcoholic Fatty Liver Disease: From Insulin Resistance to Mitochondrial Dysfunction. Revista Española de Enfermedades Digestivas, 98, 844-874.
[13] Videla, L.A. (2009) Oxidative Stress Signaling Underlying Liver Disease and Hepatoprotective Mechanisms. World Journal of Hepatology, 1, 72-78.
[14] Abdelmalek, M.F., Angulo, P., Jorgensen, R.A., Sylvestre, P.B. and Lindor KD. (2001) Betaine, a Promising New Agent for Patients with Nonalcoholic Steatohepatitis: Results of a Pilot Study. The American Journal of Gastroenterology, 96, 2711-2717.
[15] Baumgardner, J.N., Shankar, K., Hennings, L., Albano, E., Badger, T.M. and Ronis, M.J. (2008) N-Acetylcysteine Attenuates Progression of Liver Pathology in a Rat Model of Nonalcoholic Steatohepatitis. Journal of Nutrition, 138, 1872-1879.
[16] Park, K.G., Min, A.K., Koh, E.H., Kim, H.S., Kim, M.O., Park, H.S., et al. (2008) Alpha-Lipoic Acid Decreases Hepatic Lipogenesis through Adenosine Monophosphate-Activated Protein Kinase (AMPK)-Dependent and AMPK-Independent Pathways. Hepatology, 48, 1477-1486.
[17] Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., et al. (2010) Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. The New England Journal of Medicine, 362, 1675-1685.
[18] Lavine, J.E. (2000) Vitamin E Treatment of Nonalcoholic Steatohepatitis in Children: A Pilot Study. The Journal of Pediatrics, 136, 734-738.
[19] Kawanaka, M., Mahmood, S., Niiyama, G., Izumi, A., Kamei, A., Ikeda, H., et al. (2004) Control of Oxidative Stress and Reduction in Biochemical Markers by Vitamin E Treatment in Patients with Nonalcoholic Steatohepatitis: A Pilot Study. Hepatology Research, 29, 39-41.
[20] de Oliveira, A.M., Rondo, P.H., Luzia, L.A., D’Abronzo, F.H. and Illison, V.K. (2011) The Effects of Lipoic Acid and Alpha-Tocopherol Supplementation on the Lipid Profile and Insulin Sensitivity of Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Research and Clinical Practice, 92, 253-260.
[21] Lavine, J.E., Schwimmer, J.B., Van Natta, M.L., Molleston, J.P., Murray, K.F., Rosenthal, P., et al. (2011) Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents: The TONIC Randomized Controlled Trial. Journal of the American Medical Association, 305, 1659-1668.
[22] Min, A.K., Kim, M.K., Seo, H.Y., Kim, H.S., Jang, B.K., Hwang, J.S., et al. (2010) Alpha-Lipoic Acid Inhibits Hepatic PAI-1 Expression and Fibrosis by Inhibiting the TGF-Beta Signaling Pathway. Biochemical and Biophysical Research Communications, 393, 536-541.
[23] Morsy, M.A., Abdalla, A.M., Mahmoud, A.M., Abdelwahab, S.A. and Mahmoud, M.E. (2011) Protective Effects of Curcumin, Alpha-Lipoic Acid, and N-Acetylcysteine against Carbon Tetrachloride-Induced Liver Fibrosis in Rats. Journal of Physiology and Biochemistry, 68, 29-35.
[24] Packer, L. and Cadenas, E. (2011) Lipoic Acid: Energy Metabolism and Redox Regulation of Transcription and Cell Signaling. Journal of Clinical Biochemistry and Nutrition, 48, 26-32.
[25] Androne, L., Gavan, N.A., Veresiu, I.A. and Orasan, R. (2000) In Vivo Effect of Lipoic Acid on Lipid Peroxidation in Patients with Diabetic Neuropathy. In Vivo, 14, 327-330.
[26] Shay, K.P., Moreau, R.F., Smith, E.J., Smith, A.R. and Hagen, T.M. (2009) Alpha-Lipoic Acid as a Dietary Supplement: Molecular Mechanisms and Therapeutic Potential. Biochimica et Biophysica Acta (BBA)—General Subjects, 1790, 1149-1160.
[27] Parola, M., Leonarduzzi, G., Biasi, F., Albano, E., Biocca, M.E., Poli, G., et al. (1992) Vitamin E Dietary Supplementation Protects against Carbon Tetrachloride-Induced Chronic Liver Damage and Cirrhosis. Hepatology, 16, 1014-1021.
[28] Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., et al. (2007) The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hepatology, 45, 846-854.
[29] Neff, G.W., O’Brien, C.B., Reddy, K.R., Bergasa, N.V., Regev, A., Molina, E., et al. (2002) Preliminary Observation with Dronabinol in Patients with Intractable Pruritus Secondary to Cholestatic Liver Disease. The American Journal of Gastroenterology, 97, 2117-2119.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.